|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Indications and Management of Everolimus After Liver Transplantation显示文摘 | I. Bilbao G. Sapisochin C. Dopazo J.L. Lazaro L. Pou L. Castells M. Caralt L. Blanco A. Gantxegi C. Margarit R. Charco | 2009 | Transplantation Proceedings2009，，6： | 1 |
| 2 | Ownership structure and innovation: Is there a real link? 显示文摘 | Ortega- Argiles R Moreno R Caralt J S | 2005 | Annals of Regional Science2005，39，4： | 1 |
| 3 | Ownership structure and innovation: Is there a real link? 显示文摘 | Ortega-Argiles R Moreno R Caralt J S | 2005 | Annals of Regional Science2005，39，4： | 1 |
| 4 | Ventilator-associated pneumonia management in critical illness显示文摘 | Albertos R Caralt B Rello J | 2011 | Curr Opin Gastroenterol2011，27，2： | 1 |
| 5 | Ownership Structure and Innovation:Is There a Real Link?显示文摘 | R Argilés Rosina Moreno J Caralt | 2005 | Ann Reg Sci2005，39，11： | 1 |
| 6 | Magnetic resonance reveals long-term sequelae of apical ballooning syndrome显示文摘 | M. Neus Bellera José T. Ortiz Maria Teresa Caralt Jordi Pérez-Rodon Jaume Mercader Carlos Fernández-Gómez Carles Paré Magda Heras | 2008 | International Journal of Cardiology2008，，： | 1 |
| 7 | Safety of bevacizumab in metastatic breast cancer patients undergoing surgery显示文摘 | Cortes J Caralt M Delaloge S | 2012 | Eur J Cancer2012，48，4： | 1 |
| 8 | Ownership structure and innovation: Is there a real link? 显示文摘 | Ortega-Argiles R Moreno R and Caralt J S | 2005 | Annals of Re- gional Science2005，39，4： | 1 |
| 9 | Ownership Structure and Innovation ? Is There aReal Link? 显示文摘 | ORTEGA-ARGILES R MORENO R CARALT JS | 2005 | Annals of Regional Science2005，39，4： | 1 |
| 10 | Ownership structure and innovation:is there a real link?显示文摘 | Ortega-Argilés R Moreno R Caralt J S | 2005 | The Annals of Regional Science2005，39，4： | 1 |
| 11 | Ventilator associated pneumonia management in critical illness显示文摘 | Albretos R Caralt B Rello J | 2011 | Curr Opin Gastroenterol2011，27，2： | 1 |
| 12 | MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: An explant correlation显示文摘 | Marta Burrel Josep M. Llovet Carmen Ayuso Carmela Iglesias Margarita Sala Rosa Miquel Teresa Caralt Juan Ramon Ayuso Manel Solé Marcelo Sanchez Concepció Brú Jordi Bruix | 2003 | Hepatology2003，，4： | 1 |
| 13 | Cell culture from sponges:pluripotency and immortality显示文摘 | de Caralt S Uriz M J Wijffels R H | 2007 | Trends Biotechnol2007，25，10： | 1 |
| 14 | Ventilator-associated pneumonia management in critical illness显示文摘 | Albertos R Caralt B Rello J | | 0，，02： | 1 |
| 15 | In situ aquaculture methods for Dysidea avara(Demospongiae,Porifera) in the northwestern Mediterranean显示文摘 | de Caralt S Sanchez-Fontenla J Uriz M J | 2010 | Mar Drugs2010，8，6： | 1 |
| 16 | Multiple indications for everolimus after liver transplantation in current clinical practice显示文摘AIM: To assess our experience with the use and management of everolimus-based regimens post-liver transplantation and to redefine the potential role of this drug in current clinical practice.METHODS: From October 1988 to December 2012, 1023 liver transplantations were performed in 955 patients in our Unit. Seventy-four patients(7.74%) received immunosuppression with everolimus at some time post-transplantation. Demographic characteristics, everolimus indication, time elapsed from transplantation to the introduction of everolimus, doses and levels administered, efficacy, side effects, discontinuation andpost-conversion survival were analyzed. RESULTS: Mean age at the time of conversion to everolimus was 57.7 ± 10 years. Indications for conversion were: refractory rejection 31.1%, extended hepatocellular carcinoma in explanted liver 19%, post-transplant hepatocellular carcinoma recurrence 8.1%, de novo tumour 17.6%, renal insufficiency 8.1%, severe neurotoxicity 10.8%, and others 5.4%. Median time from transplantation to introduction of everolimus was 6 mo(range: 0.10-192). Mean follow-up post-conversion was 22 ± 19 mo(range: 0.50-74). The event for which the drug was indicated was resolved in 60.8% of patients, with the best results in cases of refractory rejection, renal insufficiency and neurotoxicity. Results in patients with cancer were similar to those of a historical cohort treated with other immunosuppressants. The main side effects were dyslipidemia and infections. Post-conversion acute rejection occurred in 14.9% of cases. The drug was discontinued in 28.4% of patients.CONCLUSION: Everolimus at low doses in combination with tacrolimus is a safe immunosuppressant with multiple early and late indications post-liver transplantation. | Itxarone Bilbao Cristina Dopazo Jose Lazaro Lluis Castells Mireia Caralt Gonzalo Sapisochin Ramon Charco | 2014 | World Journal of Transplantation2014，4，2： | 1 |
| 17 | Ownership Structure and Innovation: Is There a Real Link? 显示文摘 | Ortega - Argiles R Moreno R Caralt G S | 2005 | Annals of Regional Science2005，39，： | 1 |
| 18 | Ventilator-associated pneumonia management in critical illness显示文摘 | Albertos R Caralt B Rello J | 2011 | Curr Opin Gastroenterol2011，27，2： | 1 |
| 19 | Single HCC in Cirrhotic Patients: Liver Resection or Liver Transplantation? Long-term Outcome According to an Intention-to-treat Basis显示文摘 | Gonzalo Sapisochin Lluis Castells Cristina Dopazo Itxarone Bilbao Beatriz Minguez Jose Luis Lázaro Helena Allende Joaquin Balsells Mireia Caralt Ramón Charco | 2013 | Annals of Surgical Oncology2013，，4： | 1 |
| 20 | Ventilator-associated pneumonia management in critical illness 显示文摘 | Albertos R Caralt B Rello J | 2011 | Curr Opin Gastroenterol2011，27，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员